Osteonic Co Ltd

Osteonic maintains a strong liquidity position with a current ratio of 2.96 and cash and equivalents of 14,432.74 billion KRW, though its net cash position is negative after subtracting total debt of 21,776.02 billion KRW. The company's price-to-book ratio of 1.86 and debt-to-equity ratio of 0.32 suggest a relatively conservative capital structure. Profitability metrics indicate a healthy return on equity of 11.12% and return on assets of 7.47%, both exceeding the industry median for medical equipment firms. Operating income of 9,774.63 billion KRW and a gross margin of 48.6% (calculated from gross profit of 22,067.39 billion KRW on revenue of 45,393.10 billion KRW) reflect strong operational efficiency. The company's revenue is distributed across multiple product segments, with no single segment accounting for more than 30% of total revenue. Geographically, Osteonic operates in both domestic and overseas markets, though the exact revenue concentration by region is not disclosed in the input data. Looking ahead, Osteonic is projected to maintain a stable growth trajectory, with revenue expected to increase by 4.5% in the current fiscal year and 3.2% in the following year. This growth is supported by a strong free cash flow of 2,243.26 billion KRW and a capital expenditure of -8,950.78 billion KRW, indicating a focus on cost management and asset optimization. Risk factors include a medium liquidity risk due to the negative net cash position and a low dilution risk, as shares outstanding remain unchanged between basic and diluted measures. No significant dilution sources are identified in the input data, and the company has not disclosed any recent equity issuance or shelf registration. Recent events include a strong analyst consensus with a mean price target of 13,000 KRW and a mean recommendation of 1.00 (strong buy), reflecting confidence in the company's fundamentals and growth prospects.